Thoracic Neoplasms: Clinical Trials

12,102 trials for Thoracic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4813 completed, 1955 unknown, 1927 recruiting, 1358 terminated. 4480 Phase 2, 2747 Phase 1, 2030 Not applicable, 1134 Phase 3, 169 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 24480Completed 1706, Unknown 714, Recruiting 668, Terminated 610, Active not recruiting 325, Not yet recruiting 244, Withdrawn 191, Suspended 14, Enrolling by invitation 8
Phase 12747Completed 1099, Terminated 501, Recruiting 471, Active not recruiting 243, Unknown 233, Withdrawn 101, Not yet recruiting 78, Suspended 17, Enrolling by invitation 4
Not applicable2030Completed 804, Recruiting 370, Unknown 356, Not yet recruiting 152, Terminated 145, Active not recruiting 120, Withdrawn 66, Enrolling by invitation 13, Suspended 4
Phase 31134Completed 445, Recruiting 170, Unknown 165, Terminated 140, Active not recruiting 135, Not yet recruiting 51, Withdrawn 23, Enrolling by invitation 3, Suspended 2
Phase 4169Completed 76, Unknown 33, Recruiting 21, Terminated 18, Not yet recruiting 10, Active not recruiting 4, Withdrawn 4, Suspended 3
Early Phase 1119Completed 31, Unknown 24, Terminated 19, Recruiting 16, Not yet recruiting 12, Withdrawn 8, Active not recruiting 4, Enrolling by invitation 3, Suspended 2

Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer
Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer
Not applicableNot yet recruitingFranciscoVeraSerrano842028-01-012026-03-17
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
Symptom Management to Improve Completion of Patient-reported Outcome Measures
Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm
Not applicableNot yet recruitingHenry Ford Health System782027-10-012026-07-29
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods
Real-Time Image Guided Radio Therapy (IGRT) - Cancer
Not applicableNot yet recruitingUniversity of Sydney402027-06-012026-05-20
Antigen-specific T Cells Against Lung Cancer
Lung cancer-specific T cells - Lung Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202027-06-012026-11-02
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Phase 1SuspendedUNC Lineberger Comprehensive Cancer Center62027-05-202026-04-23
Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
TNG462 vopimetostat, Lorlatinib - ALK Positive Non-small Cell Lung Cancer
Phase 1Not yet recruitingDana-Farber Cancer Institute302027-04-302026-11-16
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Lung Cancer
Not yet recruitingAstraZeneca30002027-04-012026-06-02
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
Zanidatamab, Zongertinib - Non Small Cell Lung Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center242027-04-012026-10-28
Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable, Non-Targetable Stage III Non Small Cell Lung Cancer (NSCLC)
Moderately Hypofractionated Radiotherapy, Conventionally Fractionated Radiotherapy - Stage III NSCLC
Not applicableNot yet recruitingTrans Tasman Radiation Oncology Group3002027-03-302026-11-06
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma
Phase 3RecruitingNational Cancer Institute (NCI)3362027-03-022026-11-05
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2Not yet recruitingXemed LLC102027-03-012026-09-01
Virtual Reality in Lung Cancer Patients
Immersive Virtual Reality - Lung Neoplasms (D008175)
Not applicableNot yet recruitingDott.Claudio Sini602027-03-012026-08-12
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors
Artificial Intelligence-based Intervention, Best Practice, Computed Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma
Not applicableNot yet recruitingNorthwestern University342027-02-132026-10-27
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
Sacituzumab Tirumotecan (Sac-TMT) - Unresectable Thymic Carcinoma
Phase 2Not yet recruitingNational Cancer Center, Japan352027-02-012026-08-06
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingMedical University of South Carolina382027-02-012026-11-10
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
Trastuzumab Deruxtecan for Injection (T-DXd) - NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer
Phase 2Not yet recruitingCentre Leon Berard2002027-02-012026-11-13
Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Cisplatin, Carboplatin, Pemetrexed - Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Phase 3Not yet recruitingGoethe University1982027-02-012026-11-17
DK222 Study at Hopkins
[18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins62027-01-312026-09-29
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer
Phase 1SuspendedUniversity of Maryland, Baltimore502027-01-302026-09-14

Showing 20 of 12102. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (7110)  ·  Lung Neoplasms (5280)  ·  Small Cell Lung Carcinoma (1208)  ·  Breast Neoplasms (890)  ·  Neoplasms (780)  ·  Colorectal Neoplasms (696)  ·  Melanoma (576)  ·  Ovarian Neoplasms (518)  ·  Pancreatic Neoplasms (499)  ·  Neoplasm Metastasis (494)  ·  Stomach Neoplasms (413)  ·  Adenocarcinoma of Lung (404)  ·  Head and Neck Neoplasms (387)  ·  Prostatic Neoplasms (379)  ·  Carcinoma, Renal Cell (353)

Broader conditions

Neoplasms by Site (12050)  ·  Respiratory Tract Neoplasms (11873)  ·  Respiratory Tract Diseases (11766)  ·  Lung Diseases (11541)  ·  Neoplasms (11322)  ·  Bronchial Neoplasms (7951)  ·  Carcinoma, Bronchogenic (7932)  ·  Lung Neoplasms (6530)  ·  Neoplasms by Histologic Type (2456)  ·  Neoplasms, Glandular and Epithelial (1966)  ·  Digestive System Diseases (1535)  ·  Digestive System Neoplasms (1497)  ·  Skin and Connective Tissue Diseases (1433)  ·  Skin Diseases (1422)

Interventions

Carboplatin (1088)  ·  Cisplatin (822)  ·  Pemetrexed (765)  ·  pembrolizumab (592)  ·  Paclitaxel (582)  ·  Docetaxel (500)  ·  Gemcitabine (395)  ·  Radiotherapy (375)  ·  Erlotinib Hydrochloride (339)  ·  Nivolumab (325)  ·  Bevacizumab (295)  ·  Etoposide (268)  ·  durvalumab (239)  ·  Drug Therapy (229)  ·  osimertinib (212)

Sponsors

National Cancer Institute (NCI) (320)  ·  AstraZeneca (236)  ·  M.D. Anderson Cancer Center (199)  ·  Memorial Sloan Kettering Cancer Center (164)  ·  Eli Lilly and Company (161)  ·  Pfizer (140)  ·  Sun Yat-sen University (129)  ·  Bristol-Myers Squibb (113)  ·  Novartis Pharmaceuticals (111)  ·  Hoffmann-La Roche (106)  ·  Alliance for Clinical Trials in Oncology (97)  ·  Merck Sharp & Dohme LLC (95)  ·  Shanghai Chest Hospital (94)  ·  Shanghai Pulmonary Hospital, Shanghai, China (90)  ·  Boehringer Ingelheim (82)

Countries

United States (5087)  ·  China (2737)  ·  France (1171)  ·  Spain (1016)  ·  Italy (950)  ·  Canada (929)  ·  South Korea (875)  ·  United Kingdom (801)  ·  Germany (768)  ·  Taiwan (628)  ·  Australia (602)  ·  Netherlands (567)  ·  Belgium (543)  ·  Japan (522)  ·  Poland (480)

Top investigators

Mariano Provencio, MD (21)

Results publications

PMID 27130468, PMID 33538338, PMID 34393061, PMID 37419867, PMID 40311309, PMID 21714641, PMID 22586319, PMID 23442309, PMID 26291008, PMID 26291023, PMID 27718847, PMID 30207593, PMID 34870327, PMID 37465924, PMID 39113428, PMID 39462179, PMID 42820295, PMID 19692680, PMID 25175099, PMID 25881079, PMID 26104945, PMID 27959700, PMID 29658848, PMID 30280641, PMID 33337539, PMID 35537408, PMID 36184621, PMID 37934000, PMID 38642841, PMID 16757720, PMID 16966690, PMID 19801201, PMID 21502559, PMID 23816960, PMID 24705333, PMID 25436806, PMID 25490004, PMID 25589191, PMID 26028407, PMID 26051236, PMID 26768165, PMID 26823294, PMID 27458945, PMID 28445469, PMID 28472437, PMID 28501139, PMID 28885881, PMID 29151359, PMID 29290251, PMID 29293889

NIH funding

2023 (151), 2016 (69), 2017 (69), 2025 (65), 2019 (62), 2018 (61), 2015 (55), 2014 (52), U10CA031946 (52), U10CA032102 (39), P30CA033572 (32), U10CA180888 (30), P30CA012197 (27), 2009 (26), P30CA043703 (23)